Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 19/20 | 1.00 |
| ▸ | SULT1A1 | P50225 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | SNCA | P37840 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pittsburgh Compound B SCHEMBL29360193 | 1.00 | APP (1.00) | APPSULT1A1MAPTSNCA | |
| Pittsburgh Compound B SCHEMBL2055285 | 1.00 | APP (1.00) | APPSULT1A1MAPTSNCA | |
| Pittsburgh Compound B Unlabelled SCHEMBL29409766 | 1.00 | APP (1.00) | APPSULT1A1MAPTSNCA | |
| SCHEMBL12421903 | 0.92 | APP (0.85) | APPSULT1A1MAPTSNCA | |
| Pittsburgh Compound B Unlabelled SCHEMBL2055283 | 0.90 | APP (0.82) | APPSULT1A1MAPTSNCA | |
| SCHEMBL5423269 | 0.86 | APP (0.81) | APPSULT1A1MAPT | |
| SCHEMBL19372620 | 0.85 | APP (0.73) | APPSULT1A1MAPTSNCA | |
| SCHEMBL178156 | 0.84 | APP (1.00) | APPSULT1A1MAPTSNCA | |
| SCHEMBL2628262 | 0.84 | APP (1.00) | APPSULT1A1MAPTSNCA | |
| SCHEMBL2922465 | 0.83 | APP (0.72) | APPSULT1A1MAPTSNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 306 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101293878-B | Benzothiazole amino benzenes compounds, preparation method and application thereof | SHANGHAI INST APPLIED PHYSICS | 2010-12-15 | — | — | CN | claimed |
| CN-101293878-A | Benzothiazole amino benzenes compounds, preparation method and application thereof | SHANGHAI INST OF PHYSICS CAS (CN) | 2008-10-29 | — | — | CN | claimed |
| US-12594264-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| EP-3445369-B1 | VX-745 FOR USE IN THE TREATMENT OF DEMENTIA | EIP PHARMA LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12383521-B2 | Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists | IO Therapeutics, Inc (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250248962-A1 | TREATMENT OF NERVOUS SYSTEM DISORDERS USING COMBINATIONS OF RXR AGONISTS AND THYROID HORMONES | Io Therapeutics, Inc. | 2025-08-07 | — | — | US | disclosed |
| US-12259321-B2 | Method for removing background of fluorescence lifetime measurement and method for quantifying target substance | HAMAMATSU PHOTONICS K.K. (JP) | 2025-03-25 | — | — | US | disclosed |
| US-20250025581-A1 | Medical Imaging of Glycogen Synthase Kinase-3 with a PET Probe | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2025-01-23 | — | — | US | disclosed |
| EP-2247558-B2 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | LILLY CO ELI (US) | 2024-07-03 | — | — | EP | disclosed |
| CN-117940167-A | Bifunctional molecules as proteasome stimulators for improved targeted protein degradation and their use as targeted enhancing degradation agents (TARBOD) | 博思德医疗科技有限公司 | 2024-04-26 | — | — | CN | disclosed |
| US-20240091204-A1 | MODULATORS OF ALPHA-SYNUCLEIN PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-03-21 | — | — | US | disclosed |
| WO-2007033080-A2 | ALZHEIMER'S DISEASE IMAGING AGENTS | EMORY UNIVERSITY (US) | 2007-03-22 | — | — | WO | disclosed |
| US-20070031328-A1 | Radiolabeled-pegylation of ligands for use as imaging agents | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-02-08 | — | — | US | disclosed |
| US-20070031328-A1 | Radiolabeled-pegylation of ligands for use as imaging agents | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-02-08 | — | — | US | disclosed |
| WO-2006014381-A9 | USE OF THIOFLAVIN RADIOLABELED DERIVATIVES IN AMYLOID IMAGING GOR ASSESSING ANTI-AMYLOID THERAPIES | UNIV PITTSBURGH (US) | 2006-04-13 | — | — | WO | disclosed |
| WO-2006014381-A2 | USE OF THIOFLAVIN RADIOLABELED DERIVATIVES IN AMYLOID IMAGING GOR ASSESSING ANTI-AMYLOID THERAPIES | UNIVERSITY OF PITTSBURGH (US) | 2006-02-09 | — | — | WO | disclosed |
| WO-2006014382-A1 | A METHOD OF DIAGNOSING PRODROMAL FORMS OF DISEASES ASSOCIATED WITH AMYLOID DEPOSITION | UNIVERSITY OF PITTSBURGH (US) | 2006-02-09 | — | — | WO | disclosed |
| EP-1611115-A1 | BENZOTHIAZOLE DERIVATIVE COMPOUNDS, COMPOSITIONS AND USES | University of Pittsburgh (US) | 2006-01-04 | — | — | EP | disclosed |
| US-20050260126-A1 | Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein | BF RESEARCH INSTITUTE (JP) | 2005-11-24 | — | — | US | disclosed |
| WO-2004083195-A1 | BENZOTHIAZOLE DERIVATIVE COMPOUNDS, COMPOSITIONS AND USES | UNIVERSITY OF PITTSBURGH (US) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12383521-B2 | Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists | RXRG, RXRA, RXRB | APP 2181/4885SULT1A1 4054/4885MAPT 1791/4885 |
| US-20240091204-A1 | MODULATORS OF ALPHA-SYNUCLEIN PROTEOLYSIS AND ASSOCIATED METHODS OF USE | UCHL1, ADRM1, CRBN | APP 256/4885SULT1A1 4661/4885MAPT 741/4885 |
| US-12594264-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ADRM1, CRBN, SNCA | APP 414/4885SULT1A1 3881/4885MAPT 210/4885 |
| US-20050260126-A1 | Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein | PRNP, PRPH, PCNP | APP 8/4885SULT1A1 2866/4885MAPT 7/4885 |
| US-20250025581-A1 | Medical Imaging of Glycogen Synthase Kinase-3 with a PET Probe | GYS2, GYS1, PKN3 | APP 2370/4885SULT1A1 1293/4885MAPT 2564/4885 |
| US-20070031328-A1 | Radiolabeled-pegylation of ligands for use as imaging agents | EGFR, LANCL1, FLT1 | APP 4458/4885SULT1A1 2084/4885MAPT 2692/4885 |
| US-20250248962-A1 | TREATMENT OF NERVOUS SYSTEM DISORDERS USING COMBINATIONS OF RXR AGONISTS AND THYROID HORMONES | TSHR, RXRA, RXRB | APP 3906/4885SULT1A1 2553/4885MAPT 1177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.